I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchGlobeNewsWire • 06/30/25
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025GlobeNewsWire • 06/26/25
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 06/11/25
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 06/06/25
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)Zacks Investment Research • 04/14/25
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)Zacks Investment Research • 04/11/25
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewsWire • 03/21/25
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/04/25
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board MemberPRNewsWire • 01/08/25
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical ProgramPRNewsWire • 01/06/25
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung CancerPRNewsWire • 09/10/24
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business UpdatesPRNewsWire • 08/28/24
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment ConferencePRNewsWire • 08/26/24